564 related articles for article (PubMed ID: 33023239)
1. Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients.
Sabbatino F; Liguori L; Polcaro G; Salvato I; Caramori G; Salzano FA; Casolaro V; Stellato C; Col JD; Pepe S
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023239
[TBL] [Abstract][Full Text] [Related]
2. HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease.
Seliger B; Ferrone S
Methods Mol Biol; 2020; 2055():325-350. PubMed ID: 31502159
[TBL] [Abstract][Full Text] [Related]
3. Evolution of studies of HLA class I antigen processing machinery (APM) components in malignant cells.
Sabbatino F; Schwab JH; Ferrone S; Ferrone CR
Clin Transpl; 2013; ():453-63. PubMed ID: 25095541
[TBL] [Abstract][Full Text] [Related]
4. HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy.
Maggs L; Sadagopan A; Moghaddam AS; Ferrone S
Trends Cancer; 2021 Dec; 7(12):1089-1101. PubMed ID: 34489208
[TBL] [Abstract][Full Text] [Related]
5. Human leukocyte antigen expression in paired primary lung tumors and brain metastases in non-small cell lung cancer.
Failing JJ; Aubry MC; Mansfield AS
Cancer Immunol Immunother; 2021 Jan; 70(1):215-219. PubMed ID: 32696071
[TBL] [Abstract][Full Text] [Related]
6. Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.
Chang CC; Pirozzi G; Wen SH; Chung IH; Chiu BL; Errico S; Luongo M; Lombardi ML; Ferrone S
J Biol Chem; 2015 Oct; 290(44):26562-75. PubMed ID: 26381407
[TBL] [Abstract][Full Text] [Related]
7. Human leukocyte antigen-G (HLA-G) as a marker for diagnosis, prognosis and tumor immune escape in human malignancies.
Yie SM; Hu Z
Histol Histopathol; 2011 Mar; 26(3):409-20. PubMed ID: 21210353
[TBL] [Abstract][Full Text] [Related]
8. Involvement of HLA class I molecules in the immune escape of urologic tumors.
Carretero R; Gil-Julio H; Vázquez-Alonso F; Garrido F; Castiñeiras J; Cózar JM
Actas Urol Esp; 2014 Apr; 38(3):192-9. PubMed ID: 24315763
[TBL] [Abstract][Full Text] [Related]
9. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction.
Wang S; He Z; Wang X; Li H; Liu XS
Elife; 2019 Nov; 8():. PubMed ID: 31767055
[TBL] [Abstract][Full Text] [Related]
10. Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape.
Eichmüller SB; Osen W; Mandelboim O; Seliger B
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28383653
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
12. Tackling Resistance to Cancer Immunotherapy: What Do We Know?
Gondhowiardjo SA; Handoko ; Jayalie VF; Apriantoni R; Barata AR; Senoaji F; Utami IJW; Maubere F; Nuryadi E; Giselvania A
Molecules; 2020 Sep; 25(18):. PubMed ID: 32911646
[TBL] [Abstract][Full Text] [Related]
13. HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started.
Ivanova M; Shivarov V
Int J Immunogenet; 2021 Apr; 48(2):193-200. PubMed ID: 33112034
[TBL] [Abstract][Full Text] [Related]
14. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.
Campoli M; Ferrone S
Oncogene; 2008 Oct; 27(45):5869-85. PubMed ID: 18836468
[TBL] [Abstract][Full Text] [Related]
15. Defective HLA class I antigen processing machinery in cancer.
Cai L; Michelakos T; Yamada T; Fan S; Wang X; Schwab JH; Ferrone CR; Ferrone S
Cancer Immunol Immunother; 2018 Jun; 67(6):999-1009. PubMed ID: 29487978
[TBL] [Abstract][Full Text] [Related]
16. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
Kim CJ; Parkinson DR; Marincola F
J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
[TBL] [Abstract][Full Text] [Related]
17. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.
Meissner M; Reichert TE; Kunkel M; Gooding W; Whiteside TL; Ferrone S; Seliger B
Clin Cancer Res; 2005 Apr; 11(7):2552-60. PubMed ID: 15814633
[TBL] [Abstract][Full Text] [Related]
18. The role of classical and non-classical HLA class I antigens in human tumors.
Bukur J; Jasinski S; Seliger B
Semin Cancer Biol; 2012 Aug; 22(4):350-8. PubMed ID: 22465194
[TBL] [Abstract][Full Text] [Related]
19. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story.
Hicklin DJ; Marincola FM; Ferrone S
Mol Med Today; 1999 Apr; 5(4):178-86. PubMed ID: 10203751
[TBL] [Abstract][Full Text] [Related]
20. The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration.
Perea F; Bernal M; Sánchez-Palencia A; Carretero J; Torres C; Bayarri C; Gómez-Morales M; Garrido F; Ruiz-Cabello F
Int J Cancer; 2017 Feb; 140(4):888-899. PubMed ID: 27785783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
